RxNorm August 2025 Monthly Release

RxNorm August 2025 Monthly Release. NLM Tech Bull. 2025 Jul-Aug;(465):b4.

The RxNorm August 2025 monthly release will be available on August 4, 2025.

New Qualitative Distinction: Hyponatremia

We have added a new Qualitative Distinction: Hyponatremia. This is based on feedback from users requesting new RXCUIs to differentiate the generic tolvaptan 15 mg and 30 mg tablets. For example:

RXCUI	TTY	STR
849831	SBD	Hyponatremia tolvaptan 15 MG Oral Tablet [Samsca]
849835	SBD	Hyponatremia tolvaptan 30 MG Oral Tablet [Samsca]
2044355	SBD	tolvaptan 15 MG Oral Tablet [Jynarque]
2044357	SBD	tolvaptan 30 MG Oral Tablet [Jynarque]
849827	SCD	Hyponatremia tolvaptan 15 MG Oral Tablet
849833	SCD	Hyponatremia tolvaptan 30 MG Oral Tablet
2719335	SCD	tolvaptan 15 MG Oral Tablet
2719337	SCD	tolvaptan 30 MG Oral Tablet

For more information about Qualitative Distinctions in RxNorm, see the RxNorm Technical Documentation page.

New Dose Form Group: Intravesical Product

RxNorm includes a new dose form group: Intravesical Product.

The new Dose Forms within this Dose Form Group are:

• Powder for Intravesical Solution - a powder, which, upon the addition of suitable vehicles, yields a solution intended to be administered via the bladder. 
• Powder for Intravesical Suspension - a powder, which, upon the addition of suitable vehicles, yields a suspension intended to be administered via the bladder.
• Intravesical Solution - a solution intended for instillation into the bladder.
• Intravesical Suspension - a suspension intended for instillation into the bladder.

For more information about Dose Forms (TTY=DF) and Dose Form Groups (TTY=DFG), please see the RxNorm Technical Documentation Appendix 2 and Appendix 3, respectively.